Compass Therapeutics Inc. CMPX.OQ CMPX.O is expected to show no change in quarterly revenue when it reports results for the period ending December 31 2025
LSEG's mean analyst estimate for Compass Therapeutics Inc. is for a loss of 11 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 6.5% in the last three months.
Wall Street's median 12-month price target for Compass Therapeutics Inc. is $10.00, about 60% above its last closing price of $4.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.14 | -0.14 | -0.08 | Beat | 42.6 |
Jun. 30 2025 | -0.13 | -0.12 | -0.14 | Missed | -12.9 |
Mar. 31 2025 | -0.11 | -0.11 | -0.12 | Missed | -8.1 |
Dec. 31 2024 | -0.10 | -0.10 | -0.11 | Missed | -12.1 |
Sep. 30 2024 | -0.11 | -0.11 | -0.08 | Beat | 29.4 |
Jun. 30 2024 | -0.09 | -0.09 | -0.10 | Missed | -5.3 |
Mar. 31 2024 | -0.11 | -0.11 | -0.08 | Beat | 29.1 |
Dec. 31 2023 | -0.09 | -0.11 | Missed | -16.8 |
This summary was machine generated November 7 at 15:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments